FIELD: medicinal agents in the treatment of fits or degenerative diseases of the central nervous system. SUBSTANCE: the product: 2-(8-azabicyclo[3,2,1, ] oct-8-yl) alkalones of the formula 1 wherein R is H or C1-C3-alkil; Q-group is -S- or CH=CH-; X is H, halogen, OR1, COOR1, NH2, CONH2 or R1CONH wherein R1 is H or C1-C3-alkyl; D is a group of formula 2 wherein Y is H; Y1 is benzyl, unsubstituted or 4-halogen or 4- methoxysubstituted phenylthio or thienylthio where Y1 is phenyl or benzyl or Y4, or Y1 together form a group of the formula CH-C6H5 or a group of formula or a group of formula 4 wherein Y2 is hydrogen, Y3 is benzyl or (O)nSC6H5 wherein n is O or 2 and where Y2 is OH, Y3 is a group of formula 5 wherein m 0,1,2,3 or 4; R2-H is methyl or halogen or D is a group of formula 6 wherein l is 0 or 1 or L group of formula 7. Reagent 1: 3- phenylmethylene-8-azabicyclo[3,2,1] octane. Reagent 2: 4-(triisopropylsiloxy)-α-bromopropiophenone. Reagent 3: triechylamine. Reaction conditions: heating at reflux. Reagent 4: lithium aluminium hydride. Reaction conditions: in tetrahydrodfuran at room temperature. The structure of formulae 1, 2, 3, 4, 5, 6 and 7: , , , , , . EFFECT: improved properties of the drugs. 17 cl
Authors
Dates
1995-02-27—Published
1991-11-15—Filed